ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1564

Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease
Abstract Number: 1565

Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Abstract Number: 1566

Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Abstract Number: 1567

Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease
Abstract Number: 1568

A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level
Abstract Number: 1569

Can We Use Patient Reported Outcomes For Home-monitoring in SSc?
Abstract Number: 1570

Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Abstract Number: 1571

Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
Abstract Number: 1572

Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
Abstract Number: 1573

Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival
Abstract Number: 1574

A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease
Abstract Number: 1575

Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Abstract Number: 1576

Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
Abstract Number: 1577

Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Abstract Number: 1578

Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].